Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4Terminated 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 3Resectable Pancreatic Cancer 1Adenocarcinoma 1

Interventions

Cyclophosphamide 637Bevacizumab 552Paclitaxel 533Carboplatin 531Cisplatin 478pembrolizumab 452Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 371Dexamethasone 349Doxorubicin 325Nivolumab 307Fluorouracil 286Capecitabine 260Prednisone 243Oxaliplatin 242Erlotinib Hydrochloride 242Etoposide 239Lenalidomide 231Cytarabine 230Trastuzumab 227Pemetrexed 219fludarabine phosphate 207Vincristine 207Leucovorin 207Cetuximab 207Filgrastim 204Bortezomib 191Methotrexate 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has results × paricalcitol × Clear all
NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed
34 enrolled 11 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT03138720 2026-04-22

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

HonorHealth Research Institute

Phase 2 Completed
40 enrolled 22 charts
Gastrointestinal

Resectable Pancreatic Cancer

NCT04524702 2026-01-23

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Emory University

Phase 2 Completed
10 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

NCT03331562 2022-12-27

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Translational Genomics Research Institute

Phase 2 Completed
24 enrolled 14 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡